Document is current
Any future updates will be listed below
-
Authors
Almakadi, Mohammed
AlHashim, Noura
Al-Khabori, Murtadha https://orcid.org/0000-0002-2937-8838
Alzahrani, Hazzaa
Osman, Hani Yousif
Mattar, Mervat
Sabah, Ahmed
-
Funding
Funding for this research was provided by:
Medical writing support was funded by Alexion, AstraZeneca Rare Disease.
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 22 July 2025
First Online: 31 August 2025
Declarations
:
: Mohammed Almakadi has received honoraria from AstraZeneca, Novartis, Novo Nordisk, and Sobi. Noura AlHashim has no conflicts of interest to declare. Murtadha Al-Khabori has received honoraria from AstraZeneca and Sobi. Hazzaa Alzahrani has received honoraria from AstraZeneca, Novartis, Novo Nordisk, and Sobi. Hani Yousif Osman has received honoraria from AbbVie, AstraZeneca, BMS, Janssen, Novartis, Sanofi and Sobi. Mervat Mattar has received fees from AstraZeneca, BMS, Janssen, Novartis, and Pfizer. Ahmed Sabah has received speaker fees from AstraZeneca and Janssen. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: Not applicable.
: Not applicable.
